Long-acting reversible contraceptive (LARCs) methods.
Contraception
Copper intrauterine device
LARCs
Levonorgestrel-releasing intrauterine system
Long acting contraceptives
Subdermal implants
Journal
Best practice & research. Clinical obstetrics & gynaecology
ISSN: 1532-1932
Titre abrégé: Best Pract Res Clin Obstet Gynaecol
Pays: Netherlands
ID NLM: 101121582
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
02
10
2019
revised:
04
12
2019
accepted:
10
12
2019
pubmed:
6
2
2020
medline:
28
7
2020
entrez:
5
2
2020
Statut:
ppublish
Résumé
Unplanned pregnancy (UP) is a public health problem, which affects millions of women worldwide. Providing long-acting reversible contraceptive (LARC) methods is an excellent strategy to avoid or at least reduce UP, because the effectiveness of these methods is higher than other methods, and is indeed comparable to that of permanent contraception. As the initial introduction of the inert plastic intrauterine device (IUD) and of the six-rod implant, pharmaceutical companies have introduced a copper IUD (Cu-IUD), different models of levonorgestrel-releasing intrauterine system (LNG IUS), and one and two-rod implants, which certainly improved women's LARC options. The main characteristic of LARCs is that they provide high contraceptive effectiveness with a single intervention, and that they can be used for a long time. Emerging evidence from the last few years has demonstrated that it is possible to extend the use of the 52 mg LNG IUS and of the etonogestrel-implant beyond five- and three years, respectively, which adds new value to these LARCs.
Identifiants
pubmed: 32014434
pii: S1521-6934(19)30178-6
doi: 10.1016/j.bpobgyn.2019.12.002
pii:
doi:
Substances chimiques
Contraceptive Agents
0
Contraceptive Agents, Female
0
Drug Implants
0
Levonorgestrel
5W7SIA7YZW
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
28-40Informations de copyright
Copyright © 2019. Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
Declaration of Competing Interest LB and IM have received honoraria as members of advisory boards and have been invited as speakers at scientific meetings for Bayer Healthcare Pharmaceuticals and Merck. None of the other authors have any conflicts of interest to declare.